XLO
XLO clinical trials: Xilio Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Xilio Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 4
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
XLO on the catalyst calendar · XLO registry changes
- Primary completion Nov 2029Sponsor estimatePhase 1/Phase 2NCT07688577XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid TumorsXilio Development, Inc. · Metastatic NSCLC - Non-Small Cell Lung CancerRecruitingXLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 18, 2026ActualPhase 1/Phase 2NCT04896697Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsXilio Development, Inc. · Advanced Solid TumorCompletedXLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2028Sponsor estimatePhase 1/Phase 2NCT05684965XTX301 in Patients With Advanced Solid TumorsXilio Development, Inc. · Advanced Solid TumorRecruitingXLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2025ActualPhase 1/Phase 2NCT05052268XTX202 in Patients With Advanced Solid TumorsXilio Development, Inc. · Advanced Solid TumorCompletedXLOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2028Sponsor estimatePhase 2NCT07765836Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCMassachusetts General Hospital · Pancreatic Cancer MetastaticNot yet recruitingINCYCollaboratorXLOCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner